Affiliation:
1. From the Department of Anesthesiology, Mayo Clinic College of Medicine, Rochester Minn. Current address (C.H.): Institute of Clinical Pharmacology, Bayer HealthCare AG, Wuppertal, Germany.
Abstract
Aging is associated with reduced endothelial function. There is indirect evidence for reduced prostacyclin (PGI
2
)-mediated vasodilation with aging, but it is unknown whether this is because of reduced dilation to PGI
2
or altered production. In addition, the contribution of endothelial NO to PGI
2
-mediated dilation is unknown. Using plethysmography to determine forearm blood flow, we studied the effect of PGI
2
in 10 older (61 to 73 years) and 10 younger (19 to 45 years) subjects using 3 escalating intra-arterial doses of PGI
2
(epoprostenol). PGI
2
was also administered after NO synthase inhibition with
N
G
-monomethyl-
l
-arginine acetate. The percent of change in forearm vascular conductance (mean±SEM) from baseline after PGI
2
was significantly lower (
P
=0.002) in the aging individuals (52±11%, 164±23%, and 221±27% versus 115±20%, 249±19%, and 370±35%). In addition, the group-by-dose interaction was also significant (
P
=0.018). After NO synthase inhibition, the dose-response curve to PGI
2
was blunted in the young subjects but unchanged in the older subjects; the difference between the groups was no longer significant. Our data suggest that the reduced dilator effects of PGI
2
in older individuals are attributable to a reduction in the contribution of endothelial-derived NO versus alterations in the direct effects of PGI
2
on vascular smooth muscle.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Cited by
70 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献